Compare BioNano Genomics Inc (BNGO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Twist Bioscience Corp — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Twist Bioscience Corp trades at $92.62 (market cap $5.77B). The key difference: Twist Bioscience Corp is far larger — about 437.1× BioNano Genomics Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | TWST | |
|---|---|---|
Market Cap | $13.20M | $5.77B |
Sector | Health | Health |
52-Week High | $4.92 | $102.88 |
52-Week Low | $1.09 | $24.16 |
Enterprise Value | $15.81M | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.
The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
